Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.17−0.04 (-0.12%)
Close on Nov 18, 2026Market cap $6.85BP/E –Yield –
Immunovant revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
No revenue figures for Immunovant
Immunovant has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?